Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration

-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced

Related Keywords

Ireland ,United States ,Tina Ventura ,Rachel Vann ,Tim Walbert ,Linkedin ,European Group On Grave Orbitopathy ,Visa ,Exchange Commission ,Twitter ,Drug Administration ,Facebook ,Product Communications ,Nasdaq ,European Group On Grave ,Instagram ,Thyroid Eye ,Eye Disease ,Thyroid Eye Disease ,Inflammatory Bowel Disease ,Full Prescribing Information ,United States Securities ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,European Group ,Grave Orbitopathy ,Vice President ,Chief Investor Relations Officer ,Horizon ,Herapeutics ,Nnounces ,Approval ,Update ,Indication ,Language ,Tepezza ,Teprotumumab ,Brbw ,Specify ,Thyroid ,Disease ,Patients ,Regardless ,Activity ,Uration ,